Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLERO-1: everolimus + trastuzumab + paclitaxel in first-line HER2-positive advanced breast cancer
2008-006556-21Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Everolimus + trastuzumab + paclitaxel with Placebo + trastuzumab + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-006556-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006556-21.